Gonadal tumors of mice double transgenic for inhibin-alpha promoter-driven simian virus 40 T-antigen and herpes simplex virus thymidine kinase are sensitive to ganciclovir treatment.
We have previously produced transgenic (TG) mice expressing the mouse inhibin alpha-subunit promoter/Simian virus 40 T-antigen (Inhalpha/Tag) fusion gene. The mice develop gonadal somatic cell tumors at the age of 5-7 months; the ovarian tumors originate from granulosa cells, and those of the testes from Leydig cells. In the present study another TG mouse line was produced, expressing under the same inh-alpha promoter the herpes simplex virus thymidine kinase gene (Inhalpha/TK). Crossbreeding of the two TG mouse lines resulted in double TG mice (Inhalpha/TK-Inhalpha/Tag), which also developed gonadal tumors. The single (Inhalpha/Tag) and double TG (Inhalpha/TK-Inhalpha/Tag) mice, both bearing gonadal tumors, were treated at the age of 5.5-6.5 months with ganciclovir (GCV, 150 mg/kg body weight twice daily i.p.) for 14 days, or with aciclovir (ACV, 300-400 mg/kg body weight per day perorally) for 2 months. During GCV treatment, the total gonadal volume including the tumor, decreased in double TG mice by an average of 40% (P<0.05), while in single TG mice, there was a concomitant increase of 60% in gonadal size (P<0.05). GCV was also found to increase apoptosis in gonads of the double TG mice. Peroral treatment with ACV was less effective, it did not reduce significantly the gonadal volume. We also analyzed the in vitro efficacy of ACV and GCV treatments in transiently HSV-TK-transfected KK-1 murine granulosa tumor cells, originating from a single-positive Inhalpha/Tag mouse. GCV proved to be more effective and more specific than ACV in action. These results prove the principle that targeted expression of the HSV-TK gene in gonadal somatic cell tumors is potentially useful for tumor ablation by antiherpes treatment. The findings provide a lead for further development of somatic gene therapy for gonadal tumors.
Mikola
M K
MK
Department of Physiology, University of Turku, Kiinamyllynkatu 10, FIN-20520, Turku, Finland.
Rahman
N A
NA
Paukku
T H
TH
Ahtiainen
P M
PM
Vaskivuo
T E
TE
Tapanainen
J S
JS
Poutanen
M
M
Huhtaniemi
I T
IT
D000212:Acyclovir / Q000627:therapeutic use; D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000235:genetics; D000998:Antiviral Agents / Q000627:therapeutic use*; D017209:Apoptosis; D001947:Breeding; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D006106:Granulosa Cell Tumor / Q000188:drug therapy* / Q000821:virology; D007265:Inhibins / Q000235:genetics; D007984:Leydig Cell Tumor / Q000188:drug therapy* / Q000821:virology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000821:virology; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000032:analysis; D018139:Simplexvirus / Q000201:enzymology; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000821:virology; D013937:Thymidine Kinase / Q000235:genetics
D000952:Antigens, Polyomavirus Transforming; D000998:Antiviral Agents; D012333:RNA, Messenger; C094377:inhibin-alpha subunit; D007265:Inhibins; D013937:Thymidine Kinase; D015774:Ganciclovir; D000212:Acyclovir